The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Se Hoon Park
Consulting or Advisory Role - Lilly
Speakers' Bureau - Lilly
 
Jesús GarcÃa-Donas
No Relationships to Disclose
 
Robert A Huddart
Leadership - Cancer clinic london Limited liability partnership
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Speakers' Bureau - AstraZeneca; Pierre Fabre
Research Funding - Active Biotech; Bristol-Myers Squibb (Inst); Ipsen; Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; MSD Oncology; Roche/Genentech
 
Earle Frederick Burgess
Stock and Other Ownership Interests - Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Ignyta; Johnson & Johnson; McKesson; Medtronic
Consulting or Advisory Role - Bayer; Janssen; Pfizer; Roche/Genentech
Speakers' Bureau - Exelixis; Roche/Genentech
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Exelixis; Pfizer; Roche/Genentech
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Speakers' Bureau - Genentech; Medivation/Astellas
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Janssen; Novartis; Pfizer; Sanofi
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Janssen; Macrogenics
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
 
Begona Mellado
No Relationships to Disclose
 
Sergei Varlamov
No Relationships to Disclose
 
Monika Joshi
Research Funding - AstraZeneca (Inst)
 
Ignacio Duran
Honoraria - Bristol-Myers Squibb; Ipsen; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Speakers' Bureau - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi
 
Anne OHagan
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Anjali Narayan Avadhani
Employment - Janssen Research & Development
 
Bob Zhong
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Peter De Porre
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche